Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZUMA-25 Substudy D in relapsed/refractory hairy cell leukemia
NL-OMON59038Phase 2Completed
- Sponsor
- Kite Pharma
- Start
- Apr 2023
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of brexucabtagene autoleucel in hairy cell leukemia (HCL), sponsored by Kite Pharma. Primary endpoint: Objective response rate by central assessment. Started Apr 2023; status: completed.
02
Drugs
brexucabtagene autoleucel
03
Conditions
hairy cell leukemia (HCL)
Beyond the preview
Go deeper on NL-OMON59038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59038.